The 23 companies span cancer treatments, plant genetics and robotic lung devices. Combined, they pulled in just over $6.1 billion last year.

Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 10:00 AM ESTCompany ParticipantsPavel Raifeld - ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...

Generate Biomedicines has announced the pricing of its initial public offering, implying a market value of about $2 billion for the U.S. biotechnology firm. The company, which specializes in designing ...

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years.

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy ...

Clear Street Group Inc., a Wall Street broker built on cloud computing technology, has postponed its US initial public offering after cutting the target by nearly two-thirds. The company made the ...

OpenAI is raising money and considering an IPO amid concerns about its data center spending. Experts say OpenAI plans to spend so much that they worry it will be hard to bring in enough revenue. The ...

AGI reduced both the size and valuation on its NYSE IPO in response to investor pushback, blunting the Brazilian fintech’s growth ambitions. While multiple-times oversubscribed, the offering is likely ...

Michael Grimes, the longtime Morgan Stanley MS0.60%increase; green up pointing triangle rainmaker, spent years laying the groundwork for his bank to land a role leading the initial public offering of ...